Physician profile
Christopher C Max
NPI 1063592665
$6,341.09
in general payments reported to CMS, 2019-2025
34 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,395 · 2020: $904 · 2021: $885 · 2022: $960 · 2023: $1,355 · 2024: $430 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,197.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $1,146.40 | 2019-2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Bolton Medical INC | $903.47 | 2019-2022 | |
| Tela Bio, INC. | $551.18 | 2022-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Endologix LLC | $523.76 | 2019-2023 | Alto Abdominal Stent Graft System |
| Inari Medical, INC. | $451.71 | 2021-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Pfizer INC. | $295.28 | 2019-2022 | |
| Abbott Laboratories | $265.84 | 2022-2023 | Jeti Peripheral Catheter, Perclose Prostyle |
| Okami Medical, INC. | $257.62 | 2021 | |
| Janssen Pharmaceuticals, INC | $238.49 | 2019-2023 | Xarelto |
| Penumbra, INC. | $204.71 | 2020 | |
| Kerecis Limited | $176.65 | 2024-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Marigen |
| Cook Medical LLC | $149.75 | 2022 | |
| Daiichi Sankyo INC. | $146.34 | 2020-2023 | Enhertu |
| Terumo Medical Corporation | $115.88 | 2021 | |
| Cardiovascular Systems INC. | $115.02 | 2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leica Microsystems INC. | $100.93 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $99.91 | 2019-2020 | |
| Integra Lifesciences Corporation | $70.32 | 2022-2023 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Smith+Nephew, INC. | $62.57 | 2019-2024 | Collagenase Santyl, Regranex |
| Bard Peripheral Vascular, INC. | $53.91 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $47.03 | 2019 | |
| Lemaitre Vascular, INC. | $43.66 | 2019-2023 | Hydro Lemaitre Valvulotome |
| Hologic Sales and Service, LLC | $42.41 | 2024-2025 | Coolseal Generator, Magseed |
| Becton, Dickinson and Company | $36.29 | 2025 | Ultracor Twirl |
| Merck Sharp & Dohme LLC | $34.86 | 2019 | |
| Olympus America INC. | $33.53 | 2024 | Olympus |
| Acell, INC. | $27.95 | 2019 | |
| Davol INC. | $25.26 | 2023 | Phasix Mesh |
| Lilly USA, LLC | $23.62 | 2023 | Verzenio |
| Medtronic Vascular, INC. | $22.64 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $20.83 | 2024 | Exparel |
| Medtronic, INC. | $18.30 | 2022 | |
| Csl Behring | $17.80 | 2019 | |
| Convatec INC. | $17.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Max listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.